Watch out Endo: Sorrento is after your $1B+ drug with FDA OK of ZTlido
The FDA has given the green light to Sorrento Therapeutics’ painkiller patch for nerve pain, a drug that has the potential to upturn a massive market and bring in peak sales of over $1 billion.
The drug, called ZTlido, is a non-opioid way to treat posterheptic neuralgia, the chronic pain that sometimes develops with shingles. The bandage-like patch will compete with Endo International’s drug Lidoderm, which has been around for a couple decades, along with generic versions of the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
